Drug Pricing Reform
Expert articles and analysis related to drug pricing reform.
AI Summary — Last 24 Hours
Drug-pricing pressure is surfacing most clearly through utilization and affordability dynamics rather than a new CMS/HHS action in the last 24 hours: employers are facing a reported 9% cost surge driven by GLP-1 uptake and specialty pharmacy spend, forcing payers, ACO partners, and primary-care models to tighten benefit design, prescribing pathways, and outcomes-based management for cardiometabolic populations (MedCity News). At the same time, Medicare’s spending on new Alzheimer’s drugs is coming in well below expectations because of slow adoption, complex administration, and uncertain benefit.
Related Articles
Will GLP-1s Shift the Actuarial Curves for Life Expectancy? Swiss Re Models the Scenarios
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
GLP-1s, Specialty Spend, and a 9% Cost Surge: Why Employers Must Rethink Primary Care Now
GLP-1s, Specialty Spend, and a 9% Cost Surge: Why Employers Must Rethink Primary Care Now MedCity News
STAT+: Five years after disaster, a rare disease community gets new chance at treatment
Some boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.
A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).
A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)...
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal can...
Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors. American Society of Clinical Oncology - ASCO
A phase 2 study of regorafenib in metastatic/unresectable, refractory synovial sarcomas.
A phase 2 study of regorafenib in metastatic/unresectable, refractory synovial sarcomas. American Society of Clinical Oncology - ASCO